Efficacy and Safety of Botulinum Toxin Type A in the Treatment of Trigeminal Neuralgia

医学 可视模拟标度 随机对照试验 三叉神经痛 科克伦图书馆 置信区间 荟萃分析 麻醉 肉毒毒素 子群分析 内科学
作者
Xinyu Hu,Yun Xia,Jingwen Li,Xinyi Wang,Hanshu Liu,Jichuan Hu,Juan Bi,Jing Wu,Tao Wang,Zhicheng Lin,Nian Xiong
出处
期刊:The Clinical Journal of Pain [Lippincott Williams & Wilkins]
卷期号:40 (6): 383-392 被引量:1
标识
DOI:10.1097/ajp.0000000000001207
摘要

Objective: Pain management in patients with TN is challenging, as facial pain often does not respond well to conventional therapies. Botulinum toxin type A (BTX-A) has been suggested as a potential treatment option, but there is limited evidence regarding its long-term efficacy. This review aimed to analyze the current data for the use of in the treatment of trigeminal neuralgia (TN) and highlight the evidence for its efficacy and safety. Methods: A comprehensive search was conducted in various databases (PubMed, Scopus, Embase, ClinicalTrials, and Cochrane Library) to identify clinical studies evaluating the use of BTX-A in TN until October 2023. Randomized controlled trials (RCTs), single-arm studies, and stratified studies were included in the analysis. The mean difference (MD), effect size (ES), and 95% confidence interval (CI) were estimated for visual analogue scale (VAS) scores, pain episode frequency, and the proportion of responders. Results: The analysis included 23 studies, including 4 RCTs, 14 single-arm studies, and 5 stratified studies. In the RCTs, BTX-A was found to significantly reduce mean VAS scores compared with baseline (ES: −4.05; 95% CI: −6.13, −1.97; P =0.002). In 19 non-RCTs, the pooled single-arm analysis revealed that BTX-A decreased VAS scores (ES: -5.19, 95% CI: −6.05, −4.33, P <0.001) and pain attack frequency (ES: −17.85, 95% CI: −23.36, −12.34, P <0.001) from baseline to the end of follow-up. The overall proportion of responders to BTX-A treatment was also significant (95% CI: 0.653, 0.761, P =0.003). Discussion: Current evidence indicates that BTX-A injection is an effective and safe option for patients with refractory TN or not responding to medical or surgical management. However, more high-quality studies are needed to further confirm its efficacy.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
luiii完成签到,获得积分10
刚刚
Sli完成签到,获得积分10
1秒前
鹅1完成签到,获得积分10
1秒前
今后应助龙龍泷采纳,获得10
1秒前
Mhj13810发布了新的文献求助10
1秒前
1秒前
二个虎牙完成签到,获得积分10
2秒前
menxiaomei完成签到,获得积分10
2秒前
Chauncy发布了新的文献求助30
2秒前
2秒前
ccc发布了新的文献求助10
3秒前
Amy完成签到 ,获得积分10
3秒前
melone完成签到,获得积分10
3秒前
量子星尘发布了新的文献求助10
3秒前
li完成签到,获得积分10
3秒前
4秒前
kingjames完成签到,获得积分10
4秒前
道客郭完成签到,获得积分10
4秒前
5秒前
6秒前
科研狗发布了新的文献求助10
6秒前
星辰大海应助如果采纳,获得10
6秒前
布布完成签到,获得积分10
7秒前
1a完成签到 ,获得积分10
7秒前
roclie完成签到,获得积分10
8秒前
8秒前
牛马发布了新的文献求助10
9秒前
SciGPT应助fyl采纳,获得10
9秒前
一颗白菜完成签到,获得积分10
9秒前
9秒前
9秒前
我是老大应助白日幻想家采纳,获得10
9秒前
9秒前
内向万天完成签到,获得积分10
9秒前
狂野的蜡烛完成签到,获得积分10
9秒前
10秒前
10秒前
10秒前
小蘑菇应助akz采纳,获得10
11秒前
Vena完成签到,获得积分10
11秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Picture Books with Same-sex Parented Families: Unintentional Censorship 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3969222
求助须知:如何正确求助?哪些是违规求助? 3514124
关于积分的说明 11171948
捐赠科研通 3249361
什么是DOI,文献DOI怎么找? 1794799
邀请新用户注册赠送积分活动 875431
科研通“疑难数据库(出版商)”最低求助积分说明 804779